Although remission was not improved ( 88 % v. 85 % ; P = .15 ) , posthoc analyses found relapse risk ( RR ) was significantly reduced among GO recipients overall ( 3 years : 32.8 % v. 41.3 % ; HzR , 0.73 ; 95 % CI , 0.58 to 0.91 ; P = .006 ) .